Compare Incyte Corporation (INCY) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Clear Secure Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Clear Secure Inc trades at $56.59 (market cap $5.76B). The key difference: Incyte Corporation is far larger — about 4× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | YOU | |
|---|---|---|
Market Cap | $23.11B | $5.76B |
Sector | Health | Technology |
52-Week High | $118.52 | $62.36 |
52-Week Low | $67.38 | $28.84 |
Enterprise Value | $19.13B | $5.07B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Clear Secure (YOU) trades at $57.18, up 2.05% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and impressive 81.15% ROE, though valuation multiples remain elevated with a P/E of 44.82. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected, while analyst sentiment remains divided with equal buy/hold ratings.
The stock presents growth potential with expanding revenue and profitability, but faces valuation concerns and competitive pressures. Key catalysts include continued airport expansion and AWS partnership, while risks involve execution challenges and market volatility. The consensus price target of $56.67 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
